These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18813828)

  • 21. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.
    Morgan MA; Parsels LA; Parsels JD; Lawrence TS; Maybaum J
    Cell Cycle; 2006 Sep; 5(17):1983-8. PubMed ID: 16931916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Milestones in the pathogenesis and management of primary liver cancer.
    Nault JC; Cheng AL; Sangro B; Llovet JM
    J Hepatol; 2020 Feb; 72(2):209-214. PubMed ID: 31954486
    [No Abstract]   [Full Text] [Related]  

  • 25. Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells.
    Xia QS; Ishigaki Y; Zhao X; Shimasaki T; Nakajima H; Nakagawa H; Takegami T; Chen ZH; Motoo Y
    Pancreas; 2011 Jan; 40(1):55-60. PubMed ID: 20871480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
    Matthews DJ; Yakes FM; Chen J; Tadano M; Bornheim L; Clary DO; Tai A; Wagner JM; Miller N; Kim YD; Robertson S; Murray L; Karnitz LM
    Cell Cycle; 2007 Jan; 6(1):104-10. PubMed ID: 17245119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway.
    Huang H; Hu M; Zhao R; Li P; Li M
    Oncol Rep; 2013 Nov; 30(5):2467-75. PubMed ID: 24002546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.
    Karnitz LM; Flatten KS; Wagner JM; Loegering D; Hackbarth JS; Arlander SJ; Vroman BT; Thomas MB; Baek YU; Hopkins KM; Lieberman HB; Chen J; Cliby WA; Kaufmann SH
    Mol Pharmacol; 2005 Dec; 68(6):1636-44. PubMed ID: 16126823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
    Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
    J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes.
    Wehbe H; Henson R; Lang M; Meng F; Patel T
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1153-61. PubMed ID: 16982703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
    Wiesenauer CA; Yip-Schneider MT; Wang Y; Schmidt CM
    J Am Coll Surg; 2004 Mar; 198(3):410-21. PubMed ID: 14992744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
    Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD
    Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver.
    Kirchhoff T; Zender L; Merkesdal S; Frericks B; Malek N; Bleck J; Kubicka S; Baus S; Chavan A; Manns MP; Galanski M
    World J Gastroenterol; 2005 Feb; 11(8):1091-5. PubMed ID: 15754387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Separate histogenesis of combined hepatocellular and cholangiocellular carcinoma in two patients.
    Nagafuchi Y; Okamoto K; Shono M; Higure A; Todoroki H; Itoh H; Takeda S; Katumoto F; Toyoshima S
    Hepatogastroenterology; 1998; 45(20):523-7. PubMed ID: 9638442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethanol-TGFalpha-MEK signaling promotes growth of human hepatocellular carcinoma.
    Hennig M; Yip-Schneider MT; Klein P; Wentz S; Matos JM; Doyle C; Choi J; Wu H; O'Mara A; Menze A; Noble S; McKillop IH; Schmidt CM
    J Surg Res; 2009 Jun; 154(2):187-95. PubMed ID: 19321179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
    Ewald B; Sampath D; Plunkett W
    Mol Cancer Ther; 2007 Apr; 6(4):1239-48. PubMed ID: 17406032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.